Boenning & Scattergood’s Alexion Pharmaceuticals ALXN Stock Holding History

Boenning & Scattergood’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,359	Closed	-$250K	–	394
2021 Q2	$250K	Hold	1,359	–	–	0.04%	324
2021 Q1	$208K	Hold	1,359	–	–	0.04%	342
2020 Q4	$212K	Buy	+1,359	New	+$175K	0.04%	320

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Boenning & Scattergood's ALXN Position: Q3 2021 in Review

Boenning & Scattergood sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,359 shares — an estimated $250K sold.

Boenning & Scattergood first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $250K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Boenning & Scattergood reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Boenning & Scattergood sold 1,359 Alexion Pharmaceuticals shares in Q3 2021, an estimated $250K.
Boenning & Scattergood first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Boenning & Scattergood's Alexion Pharmaceuticals position peaked at $250K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Boenning & Scattergood's 13F filing for Q3 2021, filed 21 Oct 2021.